T1	intervention 0 9	Neratinib
T2	location 68 72	Asia
T4	total-participants 317 321	2840
T5	control 423 430	placebo
T7	total-participants 504 507	341
T8	intervention-participants 548 551	165
T9	control-participants 566 569	176
T10	outcome 572 615	2-year invasive disease-free survival rates
T11	iv-bin-percent 621 625	92.8
T12	cv-bin-percent 630 635	90.8%
T13	outcome 712 724	5-year rates
T14	iv-bin-percent 730 734	91.9
T15	cv-bin-percent 739 744	87.2%
T16	outcome 790 798	Diarrhea
T6	eligibility 322 372	women with early stage HER2-positive breast cancer
